Mass Torts Made Perfect Seminar
April 5-7, 2022
Build Relationships, Grow Your Practice
Mass Torts Made Perfect is more than just a conference – it’s a place for plaintiff attorneys to connect, network and learn more about the top mass tort and class action lawsuits in the country. To achieve our mission of keeping plaintiff attorneys connected, we host bi-annual conferences in the spring and fall of each year, along with webinars throughout the year that cover essential topics for individuals working in the area of plaintiff mass torts and class actions.
Whether you are an experienced trial attorney looking for the inside scoop on the latest cases or a paralegal looking to learn the basics, MTMP can help you grow your skills and practice.
Mass Torts Made Perfect offers a multitude of ways to connect with other trial attorneys throughout the year – both virtually and in person! Check out all the opportunities to grow your skills and your law firm.
Wednesday Luncheon Keynote
Drew Brees
Wednesday Night Entertainment
David Blaine
See What People Are Saying!
Mass Torts Made Perfect connects plaintiff attorneys from across the country throughout the year both online and in person. Learn more about their experience attending our webinars and conferences below!
- Superior Court Judge Sets Dates for First U.S. Zantac Trials
Superior Court Judge Evelio Grillo for the County of Alameda, who oversees the California Ranitidine Product Cases Judicial Council Coordinated Proceedings (JCCP), has set a trial date of October 10, 2022, for the first cancer case trial. Drug makers Sanofi, GlaxoSmithKline, Pfizer,... To read the entire article, click the title above.
- Panel Considers Consolidating CPAP Lawsuits
As of September 28, 2021, a total of 93 class actions had been filed against Continuous Positive Air Pressure (CPAP) maker Philips Respironics. The Judicial Panel on Multidistrict Litigation announced it will hear motions to consolidate or coordinate pretrial proceedings for these... To read the entire article, click the title above.
- FDA Requires New Warnings for Xeljanz and Other Arthritis Medicines Due to Heart Risks
The U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication (DSC) regarding the arthritis and ulcerative colitis drug Xeljanz (and Xeljanz XR), otherwise known as tofacitinib. After studying the results of a large, randomized safety clinical trial of the... To read the entire article, click the title above.
Join the MTMP Community
Sign up for our newsletter to receive reminders on registration dates, upcoming webinars and discounts!
